Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 10/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 5/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.52 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.51 |
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | FLT4 | P35916 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486324 | 0.91 | RET (0.57) | RETCHEK1KDRPDPK1TLK2 | |
| SCHEMBL3486051 | 0.91 | RET (0.53) | RETCHEK1KDRPDPK1TLK2 | |
| SCHEMBL4064004 | 0.81 | ALK (0.55) | RETKDRPDGFRBFLT3ALK | |
| SCHEMBL5362637 | 0.77 | TLK2 (0.77) | RETKDRPDPK1TLK2PDGFRB | |
| SCHEMBL13432277 | 0.73 | RET (0.69) | RETKDRPDPK1TLK2PDGFRB | |
| SCHEMBL3953189 | 0.73 | KDR (0.69) | RETCHEK1KDRPDPK1TLK2 | |
| SCHEMBL5366277 | 0.72 | RET (0.64) | RETCHEK1KDRPDPK1TLK2 | |
| SCHEMBL14301681 | 0.72 | RET (0.60) | RETKDRPDPK1TLK2PDGFRB | |
| SCHEMBL5470645 | 0.72 | RET (0.60) | RETKDRPDPK1TLK2PDGFRB | |
| SCHEMBL5470642 | 0.72 | RET (0.60) | RETKDRPDPK1TLK2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035251-A1 | BioMarkers for the Progression of Alzheimer's Disease | HE YUNSHENG | 2010-02-11 | — | — | US | disclosed |
| EP-2035582-A2 | BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE | Novartis AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007149798-A2 | BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE | NOVARTIS AG (CH) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035251-A1 | BioMarkers for the Progression of Alzheimer's Disease | LRRK2, PSEN2, CLK2 | RET 1702/4885CHEK1 52/4885KDR 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.